Compare Advance Auto Parts, Inc. (AAP) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Amylx Pharmaceuticals Inc — how do they compare? Advance Auto Parts, Inc. trades at $54.82 (market cap $3.37B), while Amylx Pharmaceuticals Inc trades at $17.83 (market cap $2.02B). The key difference: Advance Auto Parts, Inc. is the larger of the two by market cap, and Advance Auto Parts, Inc. pays a 1.79% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AAP | AMLX | |
|---|---|---|
Market Cap | $3.37B | $2.02B |
Sector | Consumer Cyclical | Health |
52-Week High | $66.50 | $18.70 |
52-Week Low | $38.75 | $6.98 |
Enterprise Value | $5.64B | $1.75B |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $55.86, down 9.22% today, reflecting recent pressure despite beating earnings estimates in three consecutive quarters. The stock shows a bearish technical signal with key support at $55 and resistance at $59. Fundamentally, revenue has declined from $11.2B in 2022 to $8.6B in 2025, though net income turned positive at $44M in 2025 after a loss in 2024. Recent news highlights a brand campaign and expanded delivery partnership with OneRail.
The outlook is mixed; analyst consensus is a Hold with a $60.89 price target, suggesting modest upside. Opportunities include margin expansion and turnaround progress, but risks involve competitive pressures, volatile cash flows, and high P/E ratio. Investor sentiment is cautious amid declining revenue trends.
AMLX trades at $17.97, down 1.64% today, with strong analyst support showing 91% buy ratings and a $30.50 consensus price target representing 70% upside potential. The stock shows bullish technical momentum with positive moving average signals, though RSI levels suggest some overbought conditions. Recent earnings showed mixed results with a Q1 2026 miss after two previous beats, while the company continues advancing its pipeline with Phase 3 data for avexitide expected in Q3 2026.
Despite negative profitability metrics and cash burn, AMLX maintains strong institutional confidence with 11 analysts covering the stock. The key catalyst remains the upcoming Phase 3 avexitide readout, though risks include ongoing class action litigation and the company's negative cash flow from operations. Current valuation at 7.31x book value reflects optimism around pipeline assets rather than current financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
